retatrutide weight loss trial Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful at 80 weeks in all doses in the retatrutide weight loss phase 2

Semaglutide first marketed as Ozempic for diabetes and later as Wegovy for obesity is heralded as a breakthrough drug for its ability to promote an average loss of 15% to 20% of a person's body weight

Advise patients with diabetes mellitus on glycemic lowering therapy that they may have an increased risk of hypoglycemia when using WEGOVY and to report signs and/or symptoms of hypoglycemia to their healthcare provider [see Warnings and Precautions (5.4)]

Conclusion Scientists have discovered that endogenous GLP-1 signaling functions as a new mechanism that controls arthritis development through its presence in joint tissues

10.1158/0008-5472.CAN-05-1568 57 KolmR